Jennifer Young-Glazer1, Alberto Cisneros1, Erin M Wilfong1,2, Scott A Smith3,4, Leslie J Crofford1,4, Rachel H Bonami5,6. 1. Department of Medicine, Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Medical Center North T3113, 1161 21st Avenue South, Nashville, TN, 37232, USA. 2. Department of Medicine, Division of Allergy, Pulmonary, and Critical Care, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. 3. Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. 4. Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. 5. Department of Medicine, Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Medical Center North T3113, 1161 21st Avenue South, Nashville, TN, 37232, USA. rachel.h.bonami@vumc.org. 6. Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. rachel.h.bonami@vumc.org.
Abstract
BACKGROUND: Anti-Jo-1 autoantibodies which recognize histidyl-tRNA synthetase identify patients with the rare rheumatologic disease, anti-histidyl-tRNA synthetase syndrome (Jo-1 ARS), a phenotypically distinct subset of idiopathic inflammatory myopathies (IIM). Jo-1-binding B cells (JBCs) are implicated in disease pathogenesis, yet they have not been studied directly. We therefore aimed to characterize JBCs to better understand how they expand and function in Jo-1 ARS. METHODS: We enrolled 10 IIM patients diagnosed with Jo-1 ARS, 4 patients with non-Jo-1 IIM, and 8 age- and sex-matched healthy controls. We phenotypically characterized peripheral blood mononuclear cells (PBMCs) ex vivo using flow cytometry to define the B cell subsets in which JBCs reside. We further tested their ability to differentiate into antibody-secreting cells following stimulation in vitro. RESULTS: The majority of JBCs were IgM+ (not class-switched). Compared to non-JBCs in the same donors, JBCs contained a higher percentage of autoimmune-prone CD21lo cells and were increased in the CD21lo IgM+ IgD- CD27+ memory subset relative to healthy donor B cells. Whereas non-JBCs were present in the anergic BND B cell subset, JBCs were nearly absent from this compartment. JBCs were detected among plasmablasts in some donors, but a reduced frequency of JBCs differentiated into CD38hi24- plasmablasts compared to non-JBCs present in the same wells following in vitro stimulation. CONCLUSIONS: JBCs are enriched for autoimmune-prone CD21lo B cells, some of which exhibit a memory phenotype in the peripheral repertoire of Jo-1 ARS patients. JBCs undergo limited class switch and show reduced capacity to differentiate into antibody-secreting cells. This suggests complex B cell biology exists beyond class-switched cells that differentiate to secrete anti-Jo-1 autoantibody (i.e., what is captured through serum autoantibody studies). New Jo-1 ARS therapies should thus ideally target non-class-switched JBCs in addition to those that have undergone IgG class-switching to most effectively block cross-talk with autoreactive T cells.
BACKGROUND: Anti-Jo-1 autoantibodies which recognize histidyl-tRNA synthetase identify patients with the rare rheumatologic disease, anti-histidyl-tRNA synthetase syndrome (Jo-1 ARS), a phenotypically distinct subset of idiopathic inflammatory myopathies (IIM). Jo-1-binding B cells (JBCs) are implicated in disease pathogenesis, yet they have not been studied directly. We therefore aimed to characterize JBCs to better understand how they expand and function in Jo-1 ARS. METHODS: We enrolled 10 IIM patients diagnosed with Jo-1 ARS, 4 patients with non-Jo-1 IIM, and 8 age- and sex-matched healthy controls. We phenotypically characterized peripheral blood mononuclear cells (PBMCs) ex vivo using flow cytometry to define the B cell subsets in which JBCs reside. We further tested their ability to differentiate into antibody-secreting cells following stimulation in vitro. RESULTS: The majority of JBCs were IgM+ (not class-switched). Compared to non-JBCs in the same donors, JBCs contained a higher percentage of autoimmune-prone CD21lo cells and were increased in the CD21lo IgM+ IgD- CD27+ memory subset relative to healthy donor B cells. Whereas non-JBCs were present in the anergic BND B cell subset, JBCs were nearly absent from this compartment. JBCs were detected among plasmablasts in some donors, but a reduced frequency of JBCs differentiated into CD38hi24- plasmablasts compared to non-JBCs present in the same wells following in vitro stimulation. CONCLUSIONS: JBCs are enriched for autoimmune-prone CD21lo B cells, some of which exhibit a memory phenotype in the peripheral repertoire of Jo-1 ARS patients. JBCs undergo limited class switch and show reduced capacity to differentiate into antibody-secreting cells. This suggests complex B cell biology exists beyond class-switched cells that differentiate to secrete anti-Jo-1 autoantibody (i.e., what is captured through serum autoantibody studies). New Jo-1 ARS therapies should thus ideally target non-class-switched JBCs in addition to those that have undergone IgG class-switching to most effectively block cross-talk with autoreactive T cells.
Entities:
Keywords:
Autoimmune diseases; Autoimmunity; B lymphocytes; Myositis
Authors: Mia J Smith; Marynette Rihanek; Brianne M Coleman; Peter A Gottlieb; Virginia D Sarapura; John C Cambier Journal: J Autoimmun Date: 2017-12-09 Impact factor: 7.094
Authors: Scott A Jenks; Kevin S Cashman; Esther Zumaquero; Urko M Marigorta; Aakash V Patel; Xiaoqian Wang; Deepak Tomar; Matthew C Woodruff; Zoe Simon; Regina Bugrovsky; Emily L Blalock; Christopher D Scharer; Christopher M Tipton; Chungwen Wei; S Sam Lim; Michelle Petri; Timothy B Niewold; Jennifer H Anolik; Greg Gibson; F Eun-Hyung Lee; Jeremy M Boss; Frances E Lund; Ignacio Sanz Journal: Immunity Date: 2018-10-09 Impact factor: 31.745
Authors: Christoph T Ellebrecht; Vijay G Bhoj; Arben Nace; Eun Jung Choi; Xuming Mao; Michael Jeffrey Cho; Giovanni Di Zenzo; Antonio Lanzavecchia; John T Seykora; George Cotsarelis; Michael C Milone; Aimee S Payne Journal: Science Date: 2016-06-30 Impact factor: 47.728
Authors: Jens Wrammert; Kenneth Smith; Joe Miller; William A Langley; Kenneth Kokko; Christian Larsen; Nai-Ying Zheng; Israel Mays; Lori Garman; Christina Helms; Judith James; Gillian M Air; J Donald Capra; Rafi Ahmed; Patrick C Wilson Journal: Nature Date: 2008-04-30 Impact factor: 49.962
Authors: Olga Kryštůfková; Hana Hulejová; Heřman F Mann; Ondřej Pecha; Ivana Půtová; Louise Ekholm; Ingrid E Lundberg; Jiří Vencovský Journal: Arthritis Res Ther Date: 2018-07-27 Impact factor: 5.156
Authors: Simon Rothwell; Hector Chinoy; Janine A Lamb; Frederick W Miller; Lisa G Rider; Lucy R Wedderburn; Neil J McHugh; Andrew L Mammen; Zoe E Betteridge; Sarah L Tansley; John Bowes; Jiří Vencovský; Claire T Deakin; Katalin Dankó; Limaye Vidya; Albert Selva-O'Callaghan; Lauren M Pachman; Ann M Reed; Øyvind Molberg; Olivier Benveniste; Pernille R Mathiesen; Timothy R D J Radstake; Andrea Doria; Jan de Bleecker; Annette T Lee; Michael G Hanna; Pedro M Machado; William E Ollier; Peter K Gregersen; Leonid Padyukov; Terrance P O'Hanlon; Robert G Cooper; Ingrid E Lundberg Journal: Ann Rheum Dis Date: 2019-05-28 Impact factor: 19.103
Authors: Erin M Wilfong; Todd Bartkowiak; Katherine N Vowell; Camille S Westlake; Jonathan M Irish; Peggy L Kendall; Leslie J Crofford; Rachel H Bonami Journal: Front Immunol Date: 2022-02-21 Impact factor: 8.786
Authors: Bryan A Joosse; James H Jackson; Alberto Cisneros; Austin B Santhin; Scott A Smith; Daniel J Moore; Leslie J Crofford; Erin M Wilfong; Rachel H Bonami Journal: Front Immunol Date: 2021-05-24 Impact factor: 8.786